Celebrating 30 Years of Clinical Use, More Than 100,000 Patients
Worldwide Have Benefited From TrueLok Circular Fixation
Products
Orthofix Medical Inc. (NASDAQ:OFIX), a leading global spine and
orthopedics company, today announced the launch of the TrueLok™
Phantom and Tornado Hinges, the latest addition to the Orthopedics
TrueLok circular frame portfolio. Both hinges are designed for use
with TrueLok circular frame offerings, including the TrueLok EVO
Ring Fixation System introduced globally last year. The TrueLok EVO
System is the only circular ring construct on the market that
consists of both radiolucent rings and struts for clearer
visualization of the bone under X-ray while also providing a
lightweight frame for patient comfort.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20230628967422/en/
TrueLok™ Phantom and Tornado Hinges are
the latest addition to the TrueLok circular frame portfolio that
has been used to treat more than 100,000 patients worldwide over
the last 30 years. (Photo: Business Wire)
“The TrueLok circular frame is the gold standard for external
fixation for complex limb reconstruction and deformity correction
procedures,” said Dr. David Frumberg, an orthopedic surgeon who
directs the Limb Restoration and Lengthening Program in New Haven,
Connecticut. “The introduction of the new Phantom and Tornado
Hinges for the TrueLok system are important advancements that have
changed how I apply circular frames by giving me the confidence
that the patient will regain a more natural joint motion. The
TrueLok EVO System with the Phantom Hinges has become my go-to
construct for equinus deformity corrections amongst other
applications.”
The TrueLok Phantom Hinge allows surgeons to achieve precise
alignment when performing joint distraction or contracture
correction procedures by maintaining the axis of rotation and joint
mobility. The hinge is radiolucent, which makes it ideal for use
with the TrueLok EVO System. The TrueLok Tornado Hinge features a
flexible spring-like design that enables the natural joint motion
to be restored following a joint distraction procedure. The Phantom
Hinges and the Tornado Hinges are both for use in ankle and knee
applications and sterile packaged for quick and easy use.
“As we celebrate the 30-year legacy of the TrueLok Ring Fixation
System this year, we are proud to continue to innovate and build on
this foundational technology that has to date been used by surgeons
to treat more than 100,000 patients worldwide,” said Kimberley
Elting, President of Global Orthopedics. “With the launch of these
two new additions, Orthofix now has the most comprehensive hinge
portfolio, demonstrating a continued commitment to invest in our
industry-leading circular frame portfolio.”
Orthofix is the only orthopedic company that offers a
comprehensive portfolio of both internal and external fixation
solutions for limb reconstruction and deformity correction. For
those attending the 2023 Limb Lengthening and Reconstruction
Society annual meeting in Lake Tahoe, CA, please visit the Orthofix
booth to learn more about the TrueLok Circular Ring Fixation
System.
The TrueLok family of products addresses the approximately $125
million circular external fixation market in the U.S. and the $278
million total global market1. TrueLok Phantom and Tornado Hinges
are now available in the U.S. and international markets and are
designed for use with the TrueLok circular frame portfolio. Learn
more about the full portfolio of Orthofix Orthopedic solutions
here.
1SmartTrak, 2023 – U.S. External Fixation Market Overview.
About Orthofix
The newly merged Orthofix-SeaSpine organization is a leading
global spine and orthopedics company with a comprehensive portfolio
of biologics, innovative spinal hardware, bone growth therapies,
specialized orthopedic solutions and a leading surgical navigation
system. Its products are distributed in more than 68 countries
worldwide.
The Company is headquartered in Lewisville, Texas and has
primary offices in Carlsbad, CA, with a focus on spine and
biologics product innovation and surgeon education, and Verona,
Italy, with an emphasis on product innovation, production, and
medical education for orthopedics. The combined company’s global
R&D, commercial and manufacturing footprint also includes
facilities and offices in Irvine, CA, Toronto, Canada, Sunnyvale,
CA, Wayne, PA, Olive Branch, MS, Maidenhead, UK, Munich, Germany,
Paris, France, and São Paulo, Brazil.
Forward-Looking Statements
This news release may include forward-looking statements within
the meaning of Section 21E of the Securities Exchange Act of 1934,
as amended, and Section 27A of the Securities Act of 1933, as
amended. In some cases, you can identify forward-looking statements
by terminology such as “may,” “will,” “should,” “expects,” “plans,”
“anticipates,” “believes,” “estimates,” “projects,” “intends,”
“predicts,” “potential,” “continue” or other comparable
terminology. Orthofix cautions you that statements included in this
news release that are not a description of historical facts are
forward-looking statements that are based on the Company’s current
expectations and assumptions. Each forward-looking statement
contained in this news release is subject to risks and
uncertainties that could cause actual results to differ materially
from those expressed or implied by such statement. Applicable risks
and uncertainties include, among others: the ability of newly
launched products to perform as designed and intended and to meet
the needs of surgeons and patients, including as a result of the
lack of robust clinical validation; and the risks identified under
the heading “Risk Factors” in Orthofix Medical Inc.’s Annual Report
on Form 10-K for the fiscal year ended December 31, 2022, which was
filed with the Securities and Exchange Commission (SEC) on March 6,
2023. The Company’s public filings with the Securities and Exchange
Commission are available at www.sec.gov. You are cautioned not to
place undue reliance on forward-looking statements, which speak
only as of the date when made. Orthofix does not intend to revise
or update any forward-looking statement set forth in this news
release to reflect events or circumstances arising after the date
hereof, except as may be required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230628967422/en/
Media Relations Denise Landry DeniseLandry@orthofix.com
214.937.2529
Investor Relations Louisa Smith, Gilmartin Group
IR@orthofix.com
Orthofix Medical (NASDAQ:OFIX)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
Orthofix Medical (NASDAQ:OFIX)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024